Article
Biochemistry & Molecular Biology
Silu Wang, Su Hwan Park, Je Sun Lim, Yun-Yong Park, Linyong Du, Jong-Ho Lee
Summary: This study investigates the non-metabolic role of PFKP in GBM immune evasion. The results show that PFKP promotes PD-L1 expression through AKT-mediated signaling, thereby enhancing GBM immune evasion. Furthermore, the study finds a positive correlation between PFKP Y64 phosphorylation and PD-L1 expression in human GBM specimens, highlighting the clinical significance of PFKP Y64 phosphorylation in GBM immune evasion.
Article
Multidisciplinary Sciences
Man Shang, Huijie Yang, Ran Yang, Tao Chen, Yuan Fu, Yeyi Li, Xianlong Fang, Kangjian Zhang, Jianju Zhang, Hui Li, Xueping Cao, Jinfa Gu, Jianwen Xiao, Qi Zhang, Xinyuan Liu, Qiujing Yu, Ting Wang
Summary: The study reveals a crucial role of MTHFD2 in promoting PD-L1 expression in tumors and facilitating tumorigenesis, potentially through the folate cycle and O-GlcNAcylation.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Qiang Zhu, Hongxing Wang, Siyuan Chai, Liang Xu, Bingyi Lin, Wen Yi, Liming Wu
Summary: Programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 (PD-1) play a role in T cell-mediated immune response against tumors. The regulation of cell surface PD-L1 is not well understood, but it is shown in this study that lysosomal degradation of PD-L1 is regulated by O-linked N-acetylglucosamine (O-GlcNAc). Inhibition of O-GlcNAc activates T cell-mediated anti-tumor immunity and combining it with PD-L1 antibody enhances the immune response. A competitive peptide inhibitor of HGS glycosylation decreases PD-L1 expression and enhances T cell-mediated immunity against tumor cells. This study reveals a link between O-GlcNAc and tumor immune evasion, providing strategies for improving PD-L1-mediated immune checkpoint blockade therapy.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Oncology
Ming Yi, Yuze Wu, Mengke Niu, Shuangli Zhu, Jing Zhang, Yongxiang Yan, Pengfei Zhou, Zhijun Dai, Kongming Wu
Summary: In this study, a bispecific antibody targeting TGF-beta and human PD-L1 was developed and showed strong antitumor effects in triple-negative breast cancer (TNBC). The bispecific antibody exhibited high binding affinity to its targets and effectively counteracted immunosuppressive signaling pathways. In vivo experiments demonstrated that the bispecific antibody had superior antitumor activity compared to monotherapies targeting the individual targets. The improved tumor microenvironment contributed to its potent antitumor effects. This study suggests that the bispecific antibody may be a promising agent for TNBC treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Kuan-Wei Su, Hung-Yun Lin, Hsien-Chung Chiu, Shin-Yu Shen, Chun A. ChangOu, Dana R. Crawford, Yu-Chen S. H. Yang, Ya-Jung Shih, Zi-Lin Li, Haw-Ming Huang, Jaqueline Whang-Peng, Yih Ho, Kuan Wang
Summary: This study found that thyroid hormone can activate ERK1/2 and STAT3 via integrin alpha v beta 3, promoting PD-L1-dependent and beta-catenin-related cell proliferation in oral cancer.
Article
Oncology
Huijie Yang, Min Xue, Peng Su, Yan Zhou, Xin Li, Zhongbo Li, Yan Xia, Chenmiao Zhang, Mingxi Fu, Xiuxia Zheng, Guosheng Luo, Tian Wei, Xinxing Wang, Yinlu Ding, Jian Zhu, Ting Zhuang
Summary: In this study, the tumor-suppressive function of RNF31 in triple negative breast cancer (TNBC) was demonstrated. It was found that RNF31 could regulate the Hippo signaling pathway and its depletion increased TNBC cell proliferation and migration. Clinical data also showed that RNF31 expression was correlated with longer relapse-free survival in TNBC patients.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Immunology
Jichun Lin, Wenshuo Fang, Zhuo Xiang, Qingqing Wang, Huapeng Cheng, Shimin Chen, Jing Fang, Jia Liu, Qiang Wang, Zhimin Lu, Leina Ma
Summary: It has been found that glycolytic enzyme hexokinase 2 (HK2) plays a crucial role in upregulating PD-L1 expression in breast cancer cells. Under high glucose conditions, HK2 acts as a protein kinase and phosphorylates IκBa at T291, leading to the degradation of IκBa and activation of NF-κB, resulting in the promotion of PD-L1 expression. Correlation analysis shows that HK2 and PD-L1 expression levels are positively correlated with immune cell infiltration and survival time of breast cancer patients. These findings highlight the potential of targeting the protein kinase activity of HK2 for breast cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Yanyan Zhang, Shuyi Zhu, Yuanyuan Du, Fan Xu, Wenbo Sun, Zhi Xu, Xiumei Wang, Peipei Qian, Qin Zhang, Jifeng Feng, Yong Xu
Summary: This study elucidates the molecular mechanism by which tumorous RelB contributes to immune evasion by inhibiting T cell immunity through the amplification of the PD-L1/PD-1-mediated immune checkpoint.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Cell Biology
Lei Liu, Ting Yu, Yanping Jin, Wei Mai, Jing Zhou, Chunbo Zhao
Summary: The study revealed that miR-15a transported by adMSCs-derived Evs could inhibit proliferation, migration, and invasion of CRC cells, promote cell apoptosis, and restrict immune evasion of CRC.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Oncology
Xue-Min Ma, Yun-Fan Luo, Fang-Fang Zeng, Chang Su, Xiong Liu, Xiang-Ping Li, Juan Lu
Summary: N-glycosylation of PD-L1 in nasopharyngeal carcinoma (NPC) is regulated by the TGF-beta 1 activated c-Jun/STT3A signaling pathway, which affects immune evasion and reduces the efficacy of cancer immunotherapy.
FRONTIERS IN ONCOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Suyeon Kim, Roun Heo, Seok Ho Song, Kwon-Ho Song, Jung Min Shin, Se Jin Oh, Hyo-Jung Lee, Jo Eun Chung, Jae Hyung Park, Tae Woo Kim
Summary: Foreignization of tumor cells by delivering a non-self foreign antigen into tumors is an effective strategy for tumor rejection. However, immune-suppressive factors in the tumor microenvironment limit the immune response against tumor antigens. Blocking PD-L1 on both tumor cells and dendritic cells can enhance the induction of tumor-reactive T cells and strengthen the anti-tumor immunity initiated by tumor-foreignization.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Biochemistry & Molecular Biology
Yung-Hung Luo, Yi-Ping Yang, Chian-Shiu Chien, Aliaksandr A. Yarmishyn, Afeez Adekunle Ishola, Yueh Chien, Yuh-Min Chen, Ping-Hsing Tsai, Tzu-Wei Lin, Mong-Lien Wang, Shih-Hwa Chiou
Summary: Lung cancer is the leading cause of death from cancer in Taiwan and worldwide. Immunotherapy has shown promising efficacy in non-small cell lung cancer (NSCLC) by blocking the PD-1/PD-L1 signaling pathway. Circular RNAs (circRNAs) have been identified as potential blood-based biomarkers to monitor the disease progression and immunotherapy efficacy. Hsa_ circ_0000190 was found to interfere with anti-PD-L1 antibody and T-cell activation, leading to immunotherapy resistance and poor prognosis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, Research & Experimental
Yujeong Moon, Man Kyu Shim, Jiwoong Choi, Suah Yang, Jinseong Kim, Wan Su Yun, Hanhee Cho, Jung Yeon Park, Yongju Kim, Joon-Kyung Seong, Kwangmeyung Kim
Summary: In this study, the researchers propose a new strategy to enhance cancer immunotherapy by using anti-PD-L1 peptide-conjugated prodrug nanoparticles (PD-NPs). The PD-NPs are taken up by cancer cells and release the drug, resulting in the disruption of immune-suppressing pathways and the enhancement of T lymphocyte immune responses. The results show that PD-NPs accumulate in tumor tissues and recruit a large amount of immune cells, leading to effective antitumor effects. This strategy has the potential to overcome the toxicity and low response rate issues in current cancer immunotherapy.
Article
Multidisciplinary Sciences
Haihua Wang, Kaiju Luo, Yuting Zhan, Shuping Peng, Songqing Fan, Weiyuan Wang
Summary: Nasopharyngeal carcinoma (NPC) is a tumor associated with Epstein-Barr virus infection and genetic/environmental factors. PD-L1 and PD-1 play a role in attenuating cellular immune responses. In this study, higher levels of PD-L1 and p-beta-cateninTyr654 expressions were found in NPC patients with distant metastases or poor prognoses, and PD-L1 was an effective indicator for predicting patients' survival status. Targeting inhibition of beta-catenin could downregulate PD-L1 expression in NPC cells, suggesting a potential new option for immune checkpoint immunosuppression in NPC.
Article
Chemistry, Medicinal
Daehyun Kim, Seung Soo Lee, Hyungwon Moon, So Yeon Park, Hak Jong Lee
Summary: The development of an immune-microbubble complex (IMC) has shown promise in reducing the toxicities associated with therapeutic antibodies and enhancing efficacy when combined with focused ultrasound. This concept could potentially maximize the therapeutic potential of antibody-based treatment regimens.
Article
Immunology
Jun Cui, Cheng Chen, Xiao Zhou, Wenju Shan, Yuhong Jian, Panpan Li, Yang Sun, Wei Yi
Summary: Bone marrow mesenchymal stem cells (BMSCs) are a promising therapy for sepsis, but metabolic syndromes threaten their effectiveness. This study investigated the potential of small extracellular vesicles from high-fat diet BMSCs in sepsis-induced liver-heart axis injury.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Binbin Zhu, Angyang Cao, Chunqu Chen, Weijian Zhou, Wenjun Luo, Yu Gui, Qinwen Wang, Zhipeng Xu, Jianhua Wang
Summary: GM6001 alleviates postoperative cognitive deficits and neuroinflammation, preserves blood-brain barrier integrity, and rescues aquaporin-4 mislocalization. MMP-9 inhibition plays a dual role in cognitive protection through direct anti-neuroinflammatory effects and regulation of aquaporin-4 membrane distribution.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Anika Sood, Valencia Fernandes, Kumari Preeti, Shruti Rajan, Dharmendra Kumar Khatri, Shashi Bala Singh
Summary: S1PR2 inhibitor improves cognitive function and skews microglia toward anti-inflammatory phenotype in type 2 diabetic mice, promising to be a potential therapy for neuroinflammation.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Haochun Guo, Ran Yu, Haijun Zhang, Wanpeng Wang
Summary: Radiation therapy is an effective treatment for thoracic malignancies, but it can cause radiation-induced lung injury (RILI), including radiation pneumonitis (RP) and radiation pulmonary fibrosis (RPF). The damage to normal lung cells during radiation treatment leads to a pulmonary inflammatory response, resulting in RP and RPF.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Guanghui Wang, Haotian Zheng, Yunzhi Xiang, Yadong Wang, Kai Wang, Xiaoyang Ren, Jiajun Du
Summary: This study identified a T-cell synthetic driver-associated prognostic model that accurately predicted prognosis and effectiveness of immunotherapy in LUAD patients. It also highlighted the role of LDHA in promoting tumor cell proliferation, invasion, and resistance to treatment, as well as its involvement in immune escape within the tumor microenvironment. These findings provide a promising new therapeutic strategy for LUAD.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Bowen Wei, Aihua Wang, Wei Liu, Qingyun Yue, Yihua Fan, Bin Xue, Siwei Wang
Summary: This study systematically analyzed the association between pSS and cuproptosis, established a predictive model based on 5 genes, explored the pathogenic mechanisms and novel therapeutic strategies for pSS, and identified EED, CBL, and NFU1 as potential targets for treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Nusrit Iqbal Andrabi, Aminur R. Sarkar, Syed Assim Haq, Diljeet Kumar, Dilpreet Kour, Diksha Saroch, Sanket Kumar Shukla, Ajay Kumar, Asha Bhagat, Asif Ali, Gurleen Kour, Zabeer Ahmed
Summary: Koenimbine and its novel semi-synthetic derivative 1G demonstrate significant anti-inflammatory effects by downregulating the nuclear factor kappa-B (NF-kappa B) signaling pathway.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Jing-Mei Lu, Xiang Xu, Fumie Aosai, Ming-Yue Zhang, Lian-Xun Piao
Summary: This study found that arctiin can improve allergic acute liver injury caused by T.g.HSP70 by inhibiting TLR4 signaling and reducing the production of inflammatory mediators.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Minxuan Xu, Fang Shi, Yongshen Gao, Shumei Han, Chensuo Huang, Qinsheng Hou, Xiaoweng Wen, Bengshi Wang, Zhenyu Zhu, Lei Zou, Mingxin Xiong, Wei Dong, Jun Tan
Summary: There is a growing body of research highlighting the involvement of metabolic imbalance and the inflammatory response in the advancement of colitis. This study recognizes arabinose as a significant protector of the intestinal mucosal barrier, reducing damage to the intestines. In addition, lower levels of arabinose in the bloodstream are associated with a higher severity of inflammatory bowel disease and colorectal cancer.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yueqing Han, Haoxin Song, Yanshan Li, Rongxin Li, Ling Chen, Bo Gao, Yijun Chen, Shuzhen Wang
Summary: The combination of tetracycline antibiotics, demeclocycline (D), chlortetracycline (C), and minocycline (M), showed therapeutic potential against liver fibrosis by inhibiting the activation of hepatic stellate cells and the MAPK signaling. This study suggests that tetracyclines may be repurposed for the treatment of liver fibrosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yu Li, Hailing Liu, Danwen Zhao, Danjie Zhang
Summary: Chronic stress can lead to lung injury, with the spleen playing a crucial role. This study found that the spleen contributes to chronic restraint stress-induced lung injury, and splenic CD11b+ cells may be an important factor in this process.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Yingqian Mi, Mengyan Tang, Qiong Wu, Yinan Wang, Qihui Liu, Pei Zhu, Xiaoyang Xue, Yuntong Liu, Xinyu Chai, Yuyang Hou, Dongmei Yan
Summary: BCG therapy can induce macrophage polarization to the M1 type, and NMAAP1 plays a crucial role in this process by regulating glycolysis and HIF-1α expression. This promotes the antitumor effect of macrophages.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Xiaosheng Liu, Tingxia Lv, Xiuxia Li, Jing Xue, Ling Lin, Lianfeng Lu, Xiaodi Li, Yang Yang, Yuanni Wu, Qiang Wei, Wei Cao, Taisheng Li
Summary: LLDT-8 exhibits notable efficacy in alleviating immune activation in both an in vivo animal model and in vitro human cell experiments, suggesting its potential as a drug for managing systemic immune activation associated with SIV/HIV infection.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Honghong Yu, Qi Li, Huimin Zhu, Chang Liu, Weiwei Chen, Lingyun Sun
Summary: The activation of the inflammasome plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE), and mesenchymal stem cells (MSC) have been shown to alleviate SLE by suppressing inflammasome activation. This study found that the NLRP3 inflammasome was activated in macrophages from SLE patients and mice, and its activation correlated with disease activity. After MSC transplantation, the severity of SLE was reduced, and NLRP3 inflammasome activation was inhibited. These findings suggest that MSC suppress inflammasome activation and provide a potential therapeutic target for SLE.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)
Article
Immunology
Wei Zhou, Dan Zeng, Shunan Liu, Yunxia Huang, Fenglin Lv, Weikang Zhou
Summary: This study found that inhibiting HDAC3 can protect the skin from atopic dermatitis by activating the Nrf2 transcription to upregulate Nrf2/HO-1 signaling pathway activity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2024)